Pexiganan

SCHEMBL487091

CC(=O)O.CC[C@H](C)[C@H](NC(=O)CN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)[C@@H](C)CC)C(C)C

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRA2A ADRA2B ADRA2C ADRB2 AGTR1 AVPR1A AVPR1B AVPR2 BDKRB2 CALCR CHRNA3 CHRNB4 ESR1 ESR2 GHSR GNRHR GSC1 HSPA8 MALT1 MC1R MC4R NOS1 NOS2 NOS3 OPRK1 OXTR RAMP1 RAMP2 RAMP3 SCN5A SSTR1 SSTR2 SSTR3 SSTR4 SSTR5 dacA dacB dacC folP ftsI mrcA mrcB mrdA rplA rplB rplC rplD rplE rplF rplJ rplK rplL rplM rplN rplO rplP rplQ rplR rplS rplT rplU rplV rplW rplX rplY rpmA rpmB rpmC rpmD rpmE rpmF rpmG rpmH rpmI rpmJ rpsA rpsB rpsC rpsD rpsE rpsF rpsG rpsH rpsI rpsJ rpsK rpsL rpsM rpsN rpsO rpsP rpsQ rpsR rpsS rpsT rpsU ykgM ykgO

The experimentally established mechanism targets of Pexiganan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 11)

	gene	UniProt	supporting neighbours	confidence
▸	PSEN1	P49768	3/20	0.58

▸	PSEN2	P49810	3/20	0.58

▸	APH1B	Q8WW43	3/20	0.58

▸	NCSTN	Q92542	3/20	0.58

▸	APH1A	Q96BI3	3/20	0.58

▸	PSENEN	Q9NZ42	3/20	0.58

▸	TFPI	P10646	1/20	0.54

▸	OPRD1	P41143	1/20	0.53

▸	RXFP1	Q9HBX9	1/20	0.52

▸	NPBWR1	P48145	2/20	0.51

▸	CTSD	P07339	1/20	0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
Acetic Acid SCHEMBL29396321	1.00	PSEN1 (0.58)	PSEN1PSEN2APH1BNCSTNAPH1A
Pexiganan SCHEMBL15247673	0.99	PSEN1 (0.58)	PSEN1PSEN2APH1BNCSTNAPH1A
Pexiganan SCHEMBL476400	0.99	PSEN1 (0.58)	PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL29405313	0.99	PSEN1 (0.58)	PSEN1PSEN2APH1BNCSTNAPH1A
Pexiganan SCHEMBL17513878	0.99	PSEN1 (0.58)	PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL29458126	0.90	GLP1R (0.58)	PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL29716608	0.90	GLP1R (0.58)	PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL29420210	0.88	TFPI (0.53)	TFPI
SCHEMBL30567725	0.88	BACE1 (0.55)	PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL30950136	0.86	GLP1R (0.65)	TFPI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 225 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
CN-119745792-A	Eye drop containing pexiganan modified hyaluronic acid, preparation method and application	济南万泉生物技术有限公司	2025-04-04	—	—	CN	claimed
US-20240285701-A1	COMPOSITIONS AND METHODS FOR TREATING SKIN CONDITIONS	THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US)	2024-08-29	—	—	US	claimed
EP-4415737-A2	COMPOSITIONS AND METHODS FOR TREATING SKIN CONDITIONS	The Trustees Of Columbia University In The City Of New York (US)	2024-08-21	—	—	EP	claimed
CN-117427230-A	Coating material with long-acting antibacterial function, preparation method thereof and medical instrument	东莞市人民医院	2024-01-23	—	—	CN	claimed
WO-2023064638-A2	COMPOSITIONS AND METHODS FOR TREATING SKIN CONDITIONS	THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US)	2023-04-20	—	—	WO	claimed
US-10953073-B2	XTEN conjugate compositions and methods of making same	AMUNIX PHARMACEUTICALS, INC. (US)	2021-03-23	—	—	US	claimed
CN-104602762-B	Stable pexiganan formula	帝普休姆制药有限公司	2017-04-05	—	—	CN	claimed
EP-2858721-B1	STABLE PEXIGANAN FORMULATION	DIPEXIUM PHARMACEUTICALS INC (US)	2016-08-17	—	—	EP	claimed
CN-104602762-A	Stable pexiganan formulation	DIPEXIUM PHARMACEUTICALS	2015-05-06	—	—	CN	claimed
EP-2858721-A1	STABLE PEXIGANAN FORMULATION	Dipexium Pharmaceuticals, Inc. (US)	2015-04-15	—	—	EP	claimed
US-20140038882-A1	Stable Pexiganan Formulation	Dipexium Pharmaceuticals LLC (US)	2014-02-06	—	—	US	claimed
WO-2013188286-A1	STABLE PEXIGANAN FORMULATION	DIPEXIUM PHARMACEUTICALS (US)	2013-12-19	—	—	WO	claimed
US-8530409-B1	Stable pexiganan formulation	Dipexium Pharmaceuticals LLC (US)	2013-09-10	—	—	US	claimed
WO-2009070564-A2	COMPOSITIONS AND METHODS FOR PREVENTION OF INFECTION IN TRANSCUTANEOUS OSSEOINTEGRATED IMPLANTS	MACROCHEM CORPORATION (US)	2009-06-04	—	—	WO	claimed
US-12534511-B2	Serum albumin-binding fibronectin type III domains	BRISTOL-MYERS SQUIBB COMPANY (US)	2026-01-27	—	—	US	disclosed
CN-119745792-A	Eye drop containing pexiganan modified hyaluronic acid, preparation method and application	济南万泉生物技术有限公司	2025-04-04	—	—	CN	disclosed
CN-112424339-B	Method for improving the production of biological products by reducing the level of endogenous proteins	隆萨有限公司	2025-03-28	—	—	CN	disclosed
EP-1035861-A1	THREONINE-CONTAINING PROTEGRINS	Intrabiotics Pharmaceuticals, Incorporated (US)	2000-09-20	—	—	EP	disclosed
US-6043220-A	Threonine-containing protegrins	INTRABIOTICS PHARMACEUTICALS, INC. (US)	2000-03-28	—	—	US	disclosed
WO-1999027945-A1	THREONINE-CONTAINING PROTEGRINS	INTRABIOTICS PHARMACEUTICALS, INC. (US)	1999-06-10	—	—	WO	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-12534511-B2	Serum albumin-binding fibronectin type III domains	FN1, ALB, FGB	PSEN1 2896/4885PSEN2 3577/4885APH1B 2331/4885
US-20140038882-A1	Stable Pexiganan Formulation	PEX3, PEX14, LPXN	PSEN1 1781/4885PSEN2 2276/4885APH1B 3916/4885
US-10953073-B2	XTEN conjugate compositions and methods of making same	XPA, TXLNA, NGLY1	PSEN1 2091/4885PSEN2 2459/4885APH1B 3487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.